AMRN Jan 2025 1.500 put
| Previous Close | 0.7600 |
| Open | 0.7600 |
| Bid | 0.6500 |
| Ask | 0.8000 |
| Strike | 1.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.7600 - 0.7600 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 112 |
GlobeNewswireAmarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT1 -- -- Approval marks seventh national reimbursement of VAZKEPA® in Europe -- -- Vianex S.A., one of the leading pharmaceutical companies in Greece, will commercialize VAZKEPA® as Amarin’s exclusive distributor in the country -- D
- GlobeNewswire
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference. H.C. Wainwright 2nd Annual BioConnect Investor Conference (May 20th, 2024; NYC)Date/Time:May 20, 2024, 4:30 p.m. ETWebcast:https://journey.ct.events/view/a719062a-400f-406f-82d4-2463ef546624
Insider MonkeyAmarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript May 1, 2024 Amarin Corporation plc misses on earnings expectations. Reported EPS is $-0.01 EPS, expectations were $-0.0075. AMRN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome […]
